{"test_cases_lookup_map": {"{\"actual_output\": \"No relevant information available.\", \"context\": null, \"expected_output\": \"Neuralink has received FDA approval for human trials and has begun recruiting participants for studies focused on helping paralyzed individuals control digital devices.\", \"hyperparameters\": null, \"input\": \"What is the current status of Neuralink clinical trials?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the question directly without any irrelevant information. Great job staying focused and concise!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"No relevant information available.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully aligned with the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink Systems Inc. received FDA Breakthrough Device Designation for the SynapseBand NeuroRehab Protocol in 2022.\",\n    \"NeuroLink Systems Inc. launched NeuroLink SDK 2.0 for developers in the second quarter of 2023.\",\n    \"NeuroLink Systems Inc. partnered with Meta for brain-controlled VR experiences in the fourth quarter of 2023.\",\n    \"NeuroLink Systems Inc. closed a Series E funding round of $310 million led by Andreessen Horowitz and SoftBank Vision Fund in the first quarter of 2024.\",\n    \"NeuroLink Systems Inc. published peer-reviewed results in Nature Neuroscience, Volume 29, Issue 7.\",\n    \"The company name is NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"NeuroLink Systems Inc. is headquartered in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\"\n] \n \nClaims:\n[] \n \nVerdicts:\n[]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}}}